ROBERT ZERBE, M.D.

Corporate Board Profile

Tech Score: 0/100

HERON THERAPEUTICS, INC. /DE/

Filing Date	Source Excerpt
2009-04-21	Robert Zerbe has served as a member of our board of directors since December 2002. Dr. Zerbe has served as the Chief Executive Officer and founder of QuatRx Pharmaceuticals Company, a private biopharmaceutical company, since 2000. Robert Zerbe received $58,062 in total compensation in 2008.
2010-04-23	Robert Zerbe, M.D. has served as a member of our Board since December 2002. Dr. Zerbe has served as the Chief Executive Officer and founder of QuatRx Pharmaceuticals Company, a private biopharmaceutical company, since 2000. Dr. Zerbe and Messrs. Rosenblatt and Turnbull each received a restricted stock award in 2009 of 70,000 shares of our common stock. The restricted stock awards vested 35,000 shares on May 27, 2009 and 35,000 shares on January 2, 2010.

Filing Date

Source Excerpt

2009-04-21

Robert Zerbe has served as a member of our board of directors since December 2002. Dr. Zerbe has served as the Chief Executive Officer and founder of QuatRx Pharmaceuticals Company, a private biopharmaceutical company, since 2000. Robert Zerbe received $58,062 in total compensation in 2008.

2010-04-23

Robert Zerbe, M.D. has served as a member of our Board since December 2002. Dr. Zerbe has served as the Chief Executive Officer and founder of QuatRx Pharmaceuticals Company, a private biopharmaceutical company, since 2000. Dr. Zerbe and Messrs. Rosenblatt and Turnbull each received a restricted stock award in 2009 of 70,000 shares of our common stock. The restricted stock awards vested 35,000 shares on May 27, 2009 and 35,000 shares on January 2, 2010.

Vericel Corp

Filing Date	Source Excerpt
2023-03-23	Robert Zerbe, M.D. has served as a director of Vericel since January 2006 and as the Chairman of our Board of Directors since October 2012. Until July 2016, Dr. Zerbe served as the Chief Executive Officer of QUATRx Pharmaceuticals Company, a venture-backed drug development company, which he co-founded in 2000. Prior to his role at QUATRx, Dr. Zerbe held several senior executive management positions with major pharmaceutical companies, including Eli Lilly and Company (from 1982 to 1993) and Pfizer (formerly Parke-Davis) (from 1993 to 2000). During his tenure at Eli Lilly, Dr. Zerbe’s clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke-Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In that capacity, he led the clinical development programs for a number of key products, including Lipitor and Neurontin. The director compensation table reflects all compensation awarded to, earned by or paid to our non-employee directors for the fiscal year ended December 31, 2022. Robert Zerbe received $90,000 in cash fees, $83,174 in stock awards, and $126,874 in option awards, totaling $300,048.
2024-03-21	Robert Zerbe, M.D., 73, Independent, Chairman of the Board, Retired Chief Executive Officer, QUATRx Pharmaceuticals Company, Director Since: 2006, Vericel Board committee(s): Audit Committee, Director compensation total: $354,641

Filing Date

Source Excerpt

2023-03-23

Robert Zerbe, M.D. has served as a director of Vericel since January 2006 and as the Chairman of our Board of Directors since October 2012. Until July 2016, Dr. Zerbe served as the Chief Executive Officer of QUATRx Pharmaceuticals Company, a venture-backed drug development company, which he co-founded in 2000. Prior to his role at QUATRx, Dr. Zerbe held several senior executive management positions with major pharmaceutical companies, including Eli Lilly and Company (from 1982 to 1993) and Pfizer (formerly Parke-Davis) (from 1993 to 2000). During his tenure at Eli Lilly, Dr. Zerbe’s clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke-Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In that capacity, he led the clinical development programs for a number of key products, including Lipitor and Neurontin. The director compensation table reflects all compensation awarded to, earned by or paid to our non-employee directors for the fiscal year ended December 31, 2022. Robert Zerbe received $90,000 in cash fees, $83,174 in stock awards, and $126,874 in option awards, totaling $300,048.

2024-03-21

Robert Zerbe, M.D., 73, Independent, Chairman of the Board, Retired Chief Executive Officer, QUATRx Pharmaceuticals Company, Director Since: 2006, Vericel Board committee(s): Audit Committee, Director compensation total: $354,641

Data sourced from SEC filings. Last updated: 2026-02-03